The following is a statement provided by BioMatrix.
“BioMatrix Specialty Pharmacy is closely monitoring the COVID-19 pandemic. Our organization has initiated proper聽response measures to ensure bleeding disorder patients maintain access to the specialty drugs required to effectively聽manage their condition throughout this emergent situation. BioMatrix is leveraging its national footprint, detailed聽business continuity plans, and extensive assets to ensure there is no disruption in patient care.
We have allocated additional resources and enacted risk mitigation plans, including early refills or additional supplies聽when and where appropriate. We have opened additional communication channels including a COVID-19 response page聽on our website and a SMS text system increasing pharmacist communication with our patients. Our team has remained聽in close contact with drug manufacturers, wholesalers, and suppliers and we do not anticipate any interruption in access聽to the products and supplies our bleeding disorder patients require.
We continue to monitor guidance from the World Health Organization, the CDC, FDA, the Boards of Pharmacy, and聽other healthcare regulatory bodies at the national, regional, state, and county levels to stay abreast of impact, guidance聽and trends. We understand the importance of continuity for the bleeding disorders community and we are confident聽that working together with organizations such as the National Hemophilia Foundation we will rise to overcome any聽challenges associated with COVID-19.”